Overview

* Rapid Micro Biosystems ( RPID ) Q2 revenue grows 10%, beating analyst expectations

* Net loss for Q2 was $11.9 mln, missing analyst estimates

* Co enters $45 mln loan facility to strengthen financial position

Outlook

* Company reaffirms full-year 2025 revenue guidance of at least $32 mln

* Company expects new loan facility to support long-term growth

* Rapid Micro Biosystems ( RPID ) aims for positive cash flow in 2025

* Company focuses on revenue growth and gross margin expansion

Result Drivers

* SERVICE REVENUE - Service revenue grew by 18%, contributing significantly to overall revenue growth

* PRODUCT REVENUE - Product revenue increased by 6%, led by mid-teens growth in consumables

* GROSS MARGIN IMPROVEMENT - Gross margin improved by seven percentage points, indicating better cost management

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $7.30 $7.03

Revenue mln mln (3

Analysts

)

Q2 EPS -$0.27

Q2 Net Miss -$11.90 -$11.10

Income mln mln (3

Analysts

)

Q2 $12.40

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Rapid Micro Biosystems Inc ( RPID ) is $8.00, about 59.3% above its August 11 closing price of $3.26

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)